Peter M. Blumberg
Senior Investigator
Center for Cancer Research
National Cancer Institute
United States of America
Biography
Dr. Blumberg received both his A.B., summa cum laude, and his Ph.D. from the Department of Biochemistry and Molecular Biology, Harvard University. He was Helen Hay Whitney fellow at the Cancer Center, Massachusetts Institute of Technology, and was assistant and associate professor of pharmacology at Harvard Medical School. Since 1981, Dr. Blumberg has been chief of the Molecular Mechanisms of Tumor Promotion Section.
Research Interest
biochemical pharmacology, structure-function analysis, cellular signaling, tumor promotion
Publications
-
Yang D, Tao J, Li L, Kedei N, Toth ZE, Czap A, Velasquez JF, Mihova D, Michalowski AM, Yuspa SH, Blumberg PM. RasGRP3, a Ras activator, contributes to signaling and the tumorigenic phenotype in human melanoma. Oncogene. 2011 Nov 10;30(45):4590.
-
Geczy T, Peach ML, El Kazzouli S, Sigano DM, Kang JH, Valle CJ, Selezneva J, Woo W, Kedei N, Lewin NE, Garfield SH. Molecular basis for failure of “atypical†C1 domain of Vav1 to bind diacylglycerol/phorbol ester. Journal of Biological Chemistry. 2012 Apr 13;287(16):13137-58.
-
Kedei N, Chen JQ, Herrmann MA, Telek A, Goldsmith PK, Petersen ME, Keck GE, Blumberg PM. Molecular systems pharmacology: isoelectric focusing signature of protein kinase Cδ provides an integrated measure of its modulation in response to ligands. Journal of medicinal chemistry. 2014 Jun 6;57(12):5356-69.
